Rhythm Pharmaceuticals, Inc.
Clinical trials sponsored by Rhythm Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company developing therapies for rare genetic obesity disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Promising drug targets obesity caused by brain damage
Disease control OngoingThis study tests a daily injection called setmelanotide to help people aged 4 and older who gained weight after a brain injury (hypothalamic obesity). The goal is to see if it reduces body weight, hunger, and improves quality of life over 52 weeks. Half of the 143 participants wi…
Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to curb hunger in Prader-Willi syndrome
Disease control OngoingThis phase 2 trial tests setmelanotide (Imcivree), a daily injection, in 18 people aged 6 to 65 with Prader-Willi syndrome who have obesity. The study will check if the drug is safe and helps reduce body weight and hunger over 52 weeks.
Phase: PHASE2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for hypothalamic obesity: Long-Term drug trial launches
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effects of a drug called bivamelagon in people with hypothalamic obesity, a condition where the brain's hunger control is damaged. About 25 participants who completed a previous study will take the drug for up to 2 years. Researchers w…
Phase: PHASE2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC